We've changed the way you complete courses

In response to user feedback we have simplified the way courses can be completed.

Until now you needed to complete the topics and modules in order, from start to finish. But from today you can complete them in any order you wish.

Just visit any topic that interests you, and when you are ready mark it as completed by clicking the green 'Mark complete' button at the bottom of the page.

Once you have completed all of the topics in a module an assessment will be provided for you.

Complete all the assessments to finish the course.

Thanks, I've got it! X

Drag the slider across the chart
Evidence for that comes from, for instance, the study with anti-CD3 antibodies, teplizumab, where they treated individuals with newly treated individuals with type 1 diabetes – the ABATE study. Here they saw a difference between those who responded to drug and those who did not respond to drug. Some individuals just had no effect whatsoever and had the same decline in C-peptide levels as the placebo-treated individuals, whereas other individuals had a very nice preservation of functional beta cell mass way beyond the six months that I showed before.
Play the audio to learn more

Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov;62(11):3766-74